english.prescrire.org > Prescrire International > N°56 - December 2001

n°56

December 2001

Issue Contents
Editorial

Real needs

p.162

New Products


Amfebutamone/buproprion for smoking cessation: nicotine replacement therapy is safer

p.163-167

Smoking cessation and nicotine replacement therapy

p.165

Topical becaplermin: a slight short-term help for some diabetic patients

p.167-169

Oxcarbazepine: an alternative to carbamazepine in partial epilepsy

p.170-174

Partial epilepsy: classifications help little with the therapeutic choice

p.172-173

Zanamivir: still no tangible impact on influenza

p.175-177

Zanamivir has no tangible impact on the spread of influenza: marketing refusal fully justified

p.176

Docetaxel: no first-line use in metastatic breast cancer

p.178-179

Chemotherapy and metastatic breast cancer: hormone therapy first

p.179

Galantamine: the fourth cholinesterase inhibitor for Alzheimer's disease

p.180-181

Trospium: no advantages over oxybutynin but price is soaring

p.190

Mofetil mycophenolate: better outcome after liver grafting

p.190

Sevelamer: second-line treatment of hyperphosphoraemia in haemodialysis patients

p.190-191

Eprosartan: hypertension: a me-too angiotensin II antagonist; no advance

p.191

Cetrorelix: no better than Gn-RH analogues in ovarian stimulation

p.191

Adverse Effects


NSAIDs and heart failure

p.182-183

Thioridazine and severe cardiac arrhythmia

p.183-184

Severe systemic effects with topical fluorouracil

p.184

Reviews


Steroid therapy of acute ENT infections: rarely indicated

p.185-187

In vitro fertilisation: many unknowns

p.187-188

Outlook


Safety of paracetamol packaging in the United Kingdom

p.189

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe